In the highly fragmented clinical research site services market, consolidation was becoming increasingly common as strategic and financial buyers looked to capitalize on benefits of scale. Realizing this, Compass Research knew that it was already in a good position to initiate a sale. To help them find the right acquirer that would strengthen their geographic presence and reduce risk for their business, we recommended a competitive approach that would attract interest from a wide range of buyers.

After opening the auction process up to numerous potential buyers, we also worked to ensure that all investors understood the unique capabilities Compass Research offered: specifically, their focus on conducting Phase I-IV clinical trials in central nervous system disorders.

Out of the many bidders, BioClinica—a clinical research technology and services partner—was ultimately selected as Compass Research’s deal partner of choice. Looking to expand their network into North America, BioClinica was a good fit for Compass Research, sharing common business goals and agreeing to attractive transaction terms. LOI to close was 50 days.